Innovent Biologics

Innovent Biologics is a biopharmaceutical company established in 2011 with a commitment to develop and commercialize high-quality innovative medicines. The company focuses on treating major diseases such as cancer. It was publicly listed on the Main Board of the Stock Exchange of Hong Kong Limited with the stock code: 01801.HK on 31 October, 2018. Innovent has developed a fully-integrated multi-functional platform including R&D, CMC, clinical development, and commercialization capabilities, resulting in a robust pipeline of 23 valuable assets in various therapeutic areas. Notably, 4 products, including TYVYT®, BYVASDA®, SULINNO®, and HALPRYZA®, have been officially approved for marketing in China, with additional assets in phase III or pivotal clinical trials. The company has invested in a biopharmaceutical production facility operating under global standards with clinical and commercial facilities compliant with cGMP standards of NMPA, FDA, and EMA. Innovent has also established a strong international team of advanced talents and entered into strategic cooperation with leading pharmaceutical companies like Eli Lilly and Incyte. Most recently, Innovent secured a Post-IPO Equity investment on 04 August 2022. As a result, the company continues on its path to realizing its slogan of developing and commercializing high-quality biopharmaceuticals that are affordable to ordinary people.